Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures

Executive Summary

The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.

You may also be interested in...

Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO

With three new approvals in January, the first anticancer about to be authorized, and a vote of confidence from the oncology physicians’ body ESMO, the European biosimilar medicines sector already seems to be picking up momentum in 2017.

Ireland Prepares New Biosimilar Policy To Improve Access, Boost Industry

Ireland is developing a new policy intended to increase the use of biosimilars, taking account of initiatives in other countries. The government says the aim is to help boost competition and access to cheaper biologicals.

Irish Drug Prices Face Annual Cuts Under New Four-Year Deal

The new Irish drug pricing deal, aimed at achieving savings of €785m over four years, provides for regular price cuts and rebates, price reductions for biologicals when biosimilar versions are marketed, and a new mechanism for dealing with high-cost medicines.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts